Cardiovascular and major journals

Evans, Marc
April 2015
Diabetes Digest;2015, Vol. 14 Issue 2, p98
The article presents abstracts related to glucose-lowering therapy to reduce the cardiovascular disease (CV) risks in patients with type 2 diabetes (T2D) which include the use of biguanides and liraglutide in risk reduction, and the impact of glycaemic index (GI) on the risk factors in CV disease.


Related Articles

  • Meta-analysis shows limited benefit of lowering blood pressure below 130/80 mm Hg in patients with type 2 diabetes. Koraishy, Farrukh M.; Peixoto, Aldo J. // Evidence Based Medicine;Dec2013, Vol. 18 Issue 6, p222 

    The authors reflect on the study titled "Intensive and standard blood pressure targets in patients with type 2 diabetes mellitus: systematic review and meta-analysis" by K. McBrien and colleagues published in a 2012 issue of the "Archives of Internal Medicine." Topics include risk of...

  • Prevalence of Complications and Clinical Audit of Management of Type 2 Diabetes Mellitus: A Prospective Hospital Based Study. KULSHRESTHA, MALINI; SETH, SEEMA; TRIPATHI, ASHUTOSH; SETH, ANINDITA; KUMAR, ANOOP // Journal of Clinical & Diagnostic Research;Nov2015, Vol. 9 Issue 11, p25 

    Introduction: Management of type 2 diabetes mellitus (DM) needs multi factorial risk reduction strategies like weight reduction, blood pressure (BP) control and lipid profile regulation, along with glycaemic control. These strategies should be implemented very early in the course of the disease...

  • Clinical course and outcomes of type-2 diabetic patients after treatment intensification for insufficient glycaemic control - results of the 2 year prospective DiaRegis follow-up. Bramlage, Peter; Gitt, Anselm K.; Schneider, Steffen; Deeg, Evelin; Tschöpe, Diethelm // BMC Cardiovascular Disorders;2014, Vol. 14 Issue 1, p1 

    Background In cases where antidiabetic monotherapy is unable to sufficiently control glucose levels in patients with type-2 diabetes, treatment needs to be intensified. Determining factors that may be predictors for the occurrence of comorbidities in these patients is essential for improving the...

  • S axagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults. Minze, Molly G.; Klein, Mary S.; Terrell, Brian T. // Clinical Medicine Insights: Endocrinology & Diabetes;2013, Issue 6, p15 

    Type 2 diabetes affects millions of people worldwide and significantly contributes to morbidity and mortality of those affected by it. Current guidelines recommend individualized treatment regimens following first line metformin therapy. Saxagliptin, a dipeptidyl-peptidase 4 inhibitor, provides...

  • Changes in multidirectional LV strain in asymptomatic patients with type 2 diabetes mellitus: a 2-year follow-up study. Roos, Cornelis J.; Scholte, Arthur J.; Kharagjitsingh, Aantje V.; Bax, Jeroen J.; Delgado, Victoria // European Heart Journal - Cardiovascular Imaging;Jan2014, Vol. 15 Issue 1, p41 

    Aims Asymptomatic patients with diabetes mellitus (DM) and normal left ventricular (LV) ejection fraction (EF) may have LV dysfunction as assessed with speckle tracking echocardiography. Whether this subtle LV dysfunction may progress or not over time remains unknown. The present evaluation...

  • Effect of Early Multifactorial Therapy Compared With Routine Care on Microvascular Outcomes at 5 Years in People With Screen-Detected Diabetes: A Randomized Controlled Trial. Sandbæk, Annelli; Griffin, Simon J.; Sharp, Stephen J.; Simmons, Rebecca K.; Borch-Johnsen, Knut; Rutten, Guy E. H. M.; van den Donk, Maureen; Wareham, Nicholas J.; Lauritzen, Torsten; Davies, Melanie J.; Khunti, Kamlesh // Diabetes Care;Jul2014, Vol. 37 Issue 7, p2015 

    OBJECTIVE To determine the benefit of multifactorial treatment on microvascular complications among people with type 2 diabetes detected by screening. RESEARCH DESIGN AND METHODS This study was a multicenter cluster randomized controlled trial in primary care with randomization at the practice...

  • Treat-to-target: type 2 diabetes. Rigby, Debbie // Australian Journal of Pharmacy;Dec2016, Vol. 97, p60 

    The article talks about the treatment of type 2 diabetes. HbA1c refers to glycated haemoglobin and is used for diagnosing diabetes. The trials conducted at United Kingdom Prospective Diabetes Study (UKPDS) on absolute cardiovascular risk assessment are mentioned. The microvascular and...

  • Type 2 diabetes: a case study. Cunningham, Priscilla; Noble, Helen // Nursing Standard;10/1/2014, Vol. 29 Issue 5, p37 

    Increased prevalence of diabetes in the community has been accompanied by an increase in diabetes in hospitalised patients. About a quarter of these patients experience a hypoglycaemic episode during their admission, which is associated with increased risk of mortality and length of stay. This...

  • Combination of Linagliptin and Metformin for the Treatment of Patients with Type 2 Diabetes. Haak, Thomas // Clinical Medicine Insights: Endocrinology & Diabetes;2015, Issue 8, p1 

    Type 2 diabetes mellitus (T2DM) is a progressive condition requiring long-term treatment. Most patients with T2DM are unable to maintain normoglycemia using metformin alone; thus, combination therapy is a pivotal part of disease management. Addition of the dipeptidyl peptidase-4 inhibitor...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics